In a mouse model of azoxymethane/DSS-induced colitis-associated cancer, administration of a MyD88 inhibitor significantly alleviated azoxymethane/DSS-inaduced colitis, resulting in reduced body weight loss and lower mortality rates [24]. This evidence concerns the gene MYD88 and cancer.